RxDoctor Payments Data

Nadim Sarkies, MD

Internal Medicine · Bakersfield, CANPI 1023015740

Payments from drug & device makers

$649in general payments, 2019–2025

Across 37 payments — averaging $17.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$145
  • AstraZeneca$115
  • Novartis$90
  • Amarin Pharma, Inc.$64
  • GSK$60
  • AbbVie$40
  • plus $135 from 7 others

What the payments were for

  • Food & beverage$649100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$649 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$121,352
Medicare patients
344
Services billed
2,185

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate104$82,221
FarxigaDapagliflozin Propanediol60$64,603
JardianceEmpagliflozin73$61,951
EliquisApixaban30$32,646
TradjentaLinagliptin33$26,774
OzempicSemaglutide21$19,311
XareltoRivaroxaban14$10,199
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$9,180
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$9,084
Lantus SolostarInsulin Glargine,hum.Rec.Anlog57$7,997
Albuterol Sulfate HfaAlbuterol Sulfate150$4,735
Rosuvastatin Calcium243$4,470
Pantoprazole Sodium394$3,416
Levothyroxine Sodium512$3,284
Atorvastatin Calcium568$3,197

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$145$88,725106 claims
MerckJanuvia$18$82,221104 claims
AstraZenecaFarxiga$115$64,60360 claims
PfizerEliquis$17$32,64630 claims
Novo NordiskOzempic$14$19,31121 claims
GSKTrelegy Ellipta$60$9,18014 claims
AbbVieSynthroid$40$1,55224 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →